.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Julphar
Cerilliant
Baxter
Teva
Novartis
US Department of Justice
Colorcon
Boehringer Ingelheim
Federal Trade Commission

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050578

« Back to Dashboard
NDA 050578 describes FORTAZ, which is a drug marketed by Teligent and is included in two NDAs. It is available from two suppliers. Additional details are available on the FORTAZ profile page.

The generic ingredient in FORTAZ is ceftazidime sodium. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ceftazidime sodium profile page.

Summary for NDA: 050578

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 050578

Ingredient-typeCephalosporins

Suppliers and Packaging for NDA: 050578

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FORTAZ
ceftazidime
INJECTABLE;INJECTION 050578 NDA Covis Pharmaceuticals, Inc. 24987-377 24987-377-10 10 VIAL, SINGLE-DOSE in 1 TRAY (24987-377-10) > 17 mL in 1 VIAL, SINGLE-DOSE
FORTAZ
ceftazidime
INJECTABLE;INJECTION 050578 NDA Covis Pharmaceuticals, Inc. 24987-378 24987-378-10 10 VIAL, SINGLE-DOSE in 1 TRAY (24987-378-10) > 26 mL in 1 VIAL, SINGLE-DOSE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength500MG/VIAL
Approval Date:Jul 19, 1985TE:APRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength1GM/VIAL
Approval Date:Jul 19, 1985TE:APRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength2GM/VIAL
Approval Date:Jul 19, 1985TE:APRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Queensland Health
Johnson and Johnson
Boehringer Ingelheim
Cantor Fitzgerald
Covington
McKinsey
Baxter
Fish and Richardson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot